Jensen, Donald <br/><br/>
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.  [electronic resource] 

 -  Journal of hepatology  Jul 2015 
 - 30-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1600-0641 
<br/><br/><label>Standard No.: </label>10.1016/j.jhep.2015.02.018  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antiviral Agents--administration & dosage<br/>Carbamates<br/>DNA, Viral--genetics<br/>Drug Administration Schedule<br/>Drug Carriers<br/>Drug Therapy, Combination<br/>Female<br/>Follow-Up Studies<br/>Genotype<br/>Hepacivirus--genetics<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Imidazoles--administration & dosage<br/>Interferon-alpha--administration & dosage<br/>Isoquinolines--administration & dosage<br/>Male<br/>Middle Aged<br/>Polyethylene Glycols--administration & dosage<br/>Pyrrolidines<br/>Recombinant Proteins--administration & dosage<br/>Ribavirin--administration & dosage<br/>Sulfonamides--administration & dosage<br/>Treatment Outcome<br/>Valine--analogs & derivatives<br/>Viral Load--genetics<br/>Young Adult